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a b s t r a c t
APOBEC3G (A3G) is a cytidine deaminase that restricts HIV-1 replication by inducing G-to-A hypermu-
tation in viral DNA; deamination-independent mechanisms are also implicated. HIV-1 Vif protein
counteracts A3G by inducing its proteasomal degradation. Thus, the Vif–A3G axis is a potential
therapeutic target. To identify compounds that inhibit Vif:A3G interaction, a 307,520 compound library
was tested in a TR-FRET screen. Two identiﬁed compounds, redoxal and lomofungin, inhibited HIV-1
replication in peripheral blood mononuclear cells. Lomofungin activity was linked to A3G, but not
pursued further due to cytotoxicity. Redoxal displayed A3G-dependent restriction, inhibiting viral
replication by stabilizing A3G protein levels and increasing A3G in virions. A3G-independent activity
was also detected. Treatment with uridine or orotate, intermediates of pyrimidine synthesis, diminished
redoxal-induced stabilization of A3G and antiviral activity. These results identify redoxal as an inhibitor
of HIV-1 replication and suggest its ability to inhibit pyrimidine biosynthesis suppresses viral replication
by augmenting A3G antiviral activity.
& 2015 Elsevier Inc. All rights reserved.
Background
While current antiretroviral therapies prolong the lifespan of
people living with HIV/AIDS, they fail to completely clear the virus
reservoir, resulting in a chronic infection (Ketseoglou et al., 2014;
Kumar et al., 2014; Li et al., 2012). These antiretroviral regimens
also have signiﬁcant side effects, including lipodystrophy, hyper-
glycemia, renal dysfunction, osteoporosis, and cardiovascular dis-
ease (Carr and Cooper, 2000; Kalayjian et al., 2012; Max and
Sherer, 2000; Towner et al., 2012). Due to side effects as well as the
common problem of drug resistance, novel antiretrovirals are
needed to offer new treatment options. With exception of CCR5
antagonists and other entry inhibitors, current HIV-1 drug regi-
mens only target the viral enzymes.
A3G, a cellular antiviral restriction factor, and its viral antago-
nist Vif (viral infectivity factor) have recently emerged as attractive
targets for novel anti-HIV-1 therapeutics (Aires da Silva et al.,
2004; Goncalves et al., 2002; Malim and Bieniasz, 2012; Smith
et al., 2009; Strebel, 2013). A3G is a member of the APOBEC3 (A3)
family of single-stranded (ss) DNA cytidine deaminases that serve
as critical post-entry barriers to retroviral replication (Esnault
et al., 2005, 2006; Harris et al., 2003; Mangeat et al., 2003). All
A3 family members (A3A, A3B, A3C, A3D, A3F, A3G, and A3H) have
known antiviral activity (Goila-Gaur and Strebel, 2008; Malim,
2009). A common feature characterizing the A3 family is the
presence of a catalytic domain composed of a conserved zinc-
binding motif, which catalyzes the hydrolytic deamination of
deoxycytidine, converting it to deoxyuridine (Wang et al., 2011).
A3G is a potent antiretroviral host factor widely expressed in
hematopoietic cells, including CD4þ T cells and myeloid cells
(Bonavia et al., 2011). In the absence of a functional Vif protein,
A3G protein is incorporated into HIV-1 virions and deaminates
cytidine to uridine in the viral minus-strand DNA during reverse
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transcription, resulting in G-to-A hypermutation and premature
degradation of newly synthesized viral DNA (Harris et al., 2003;
Mangeat et al., 2003; Miyagi et al., 2007; Schumacher et al., 2008;
Zhang et al., 2003). A3G has also been shown to inhibit HIV-1
replication via deamination-independent mechanisms (Belanger
et al., 2013; Bishop et al., 2006; Chaurasiya et al., 2014; Gillick
et al., 2013; Guo et al., 2007; Holmes et al., 2007; Luo et al., 2007;
Newman et al., 2005).
HIV-1 and other lentiviruses overcome this antiviral activity of
A3G via the viral accessory protein Vif. Vif binds to A3G prior to its
incorporation into virions and induces its ubiquitination and
degradation via the 26S proteasome. Vif must also associate with
the core-binding factor subunit beta (CBF-β) and Cullin 5 (Cul5)-
EloB-EloC E3 ligase complex to exert its anti-A3G effects through
proteasomal degradation pathways (Guo et al., 2014; Jager et al.,
2012; Mehle et al., 2004, 2006; Wang et al., 2013). Vif may also
inhibit A3G through mechanisms independent of proteasomal
degradation (Kao et al., 2003, 2004). Small molecules that inhibit
HIV-1 Vif function in vitro have been identiﬁed, but these com-
pounds do not inhibit the Vif–A3G interaction (Cen et al., 2010;
Matsui et al., 2014; Nathans et al., 2008; Pan et al., 2015; Zuo et al.,
2012).
In a recent study (Pery et al., 2015), we reported using a high-
throughput screen (HTS) for inhibitors of the Vif–A3G interaction
and identiﬁcation of a novel compound N.41 that attenuates HIV-1
replication by liberating A3G from Vif regulation, leading to an
increase in its innate antiviral activity. Here, we report two
additional compounds identiﬁed in the HTS, lomofungin and
redoxal, which exhibit potent antiviral activity against HIV-1
replication in PBMCs. Unexpectedly, we found that redoxal, a
known inhibitor of the de novo pyrimidine biosynthesis pathway,
attenuates HIV-1 replication by stabilizing the A3G protein,
increasing its incorporation into virions and thereby augmenting
its innate antiviral activity. Antiviral activity independent of A3G
was also detected.
Results
Identiﬁcation of redoxal and lomofungin as inhibitors of Vif–A3G
interaction
To identify compounds that inhibit the interaction between
HIV-1 Vif and A3G, we used a homogeneous time-resolved
ﬂuorescence resonance energy transfer (TR-FRET) high-
throughput screening assay (Fig. 1A) (Mehle et al., 2007; Pery
et al., 2009, 2015). In this assay, interaction between a puriﬁed
GST-Vif protein fragment that includes the A3G binding site (1–94
amino acids; GST-Vif) (Dang et al., 2010a, 2010b; Kouno et al.,
2015; Mehle et al., 2007; Pery et al., 2009; Russell and Pathak,
2007; Yamashita et al., 2008), and a synthetic biotinylated A3G
peptide corresponding to amino acids 110–148, which encom-
passes the Vif-binding site (Bogerd et al., 2004; Huthoff and
Malim, 2007; Mangeat et al., 2004; Schrofelbauer et al., 2004), is
detected by Europium (Eu-donor ﬂuorophore)-labeled anti-GST
antibodies and Streptavidin-Ulight (acceptor ﬂuorophore). Inter-
action between Vif and A3G brings Eu and Ulight into close
proximity, supporting energy transfer between these molecules;
this energy transfer is then measured as a FRET signal and
attenuation of Vif–A3G interaction results in signal reduction.
A 307,520 compound library was screened and active hits were
identiﬁed as described (Pery et al., 2015). The complete results of
the HTS can be found at Pubchem under AID 1117320 (https://
pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid¼1117320). The sec-
ondary TR-FRET-based dose–response assay and counter screens
for speciﬁcity validated redoxal and lomofungin as promising
compounds for subsequent evaluation (Fig. 1B). Lomofungin, a
natural product compound ﬁrst isolated from the soil-dwelling
Gram-positive bacteria Streptomyces lomodensis, was previously
shown to inhibit RNA synthesis in yeast, fungi, and Gram-positive
and Gram-negative bacteria (Cano et al., 1973; Johnson and Dietz,
1969; Klo et al., 1973). Lomofungin was subsequently identiﬁed as
an inhibitor of botulinum neurotoxin light chain protease
(Eubanks et al., 2010) and as a potential therapeutic for myotonic
dystrophy type 1 (Hoskins et al., 2014a). Redoxal is a synthetic
compound originally identiﬁed by a computer algorithm as an
inhibitor of dihydroorotate dehydrogenase (DHODH), an essential
enzyme in the de novo pyrimidine synthesis pathway (Fig. 1C)
(Cleaveland et al., 1995; Knecht and Lofﬂer, 2000). Redoxal inhibits
pyrimidine biosynthesis through this mechanism, and was pre-
viously shown to inhibit DHODH in Candida albicans and exert
antiviral activity against West Nile virus (Chung et al., 2010;
Zameitat et al., 2006).
Redoxal and lomofungin inhibit HIV-1 replication in PBMCs
The next step in our screening pipeline included a cell-based
assay to identify compounds that attenuate Vif-dependent degra-
dation of A3G in 293T cells and an assay testing antiviral activity in
PBMCs. Although redoxal and lomofungin had little effect on Vif-
dependent degradation of A3G in the YFP-A3G assay, these
compounds had strong antiviral activity when tested against
HIV-1 replication in PBMCs. Redoxal had an IC50 as low as
1.37 mM and TC504100 mM, while lomofungin had an IC50 as low
as 0.07 mM and TC50¼3.6 mM when tested against HIV-1Ba-L
replication in PBMCs (Fig. 2A). However, further examination of
lomofungin antiviral activity revealed a low therapeutic index
(TI50) in PBMCs due to its cytotoxicity (data not shown).
Further testing of lomofungin and compound analogs
The antiviral activity of lomofungin was further examined by
testing its effects on HIV–1NL4-3 replication in H9 (A3G-expressing;
A3Gþ) and SupT1 (A3G-negative; A3G-) T cells. At 62.5 and
125 nM, lomofungin demonstrated strong antiviral activity in H9
cells expressing A3G but not in SupT1 T cells lacking A3G expres-
sion, but concentrations greater than 125 nM caused signiﬁcant
cytotoxicity in both cell lines (Additional File 1). To address and
potentially ameliorate this cell toxicity, lomofungin analogs were
identiﬁed and tested for viral suppression and cytotoxicity in
PBMCs (Additional Files 2 and 3). The most promising analog,
Analog 4, showed no signiﬁcant cytotoxicity but had an IC50 range
of 17.8–24.3 mM when tested against replication of several HIV-1
isolates, indicating weak antiviral activity. Therefore, further studies
of lomofungin were not pursued.
Redoxal exhibits A3G-dependent antiviral activity against diverse
HIV-1 isolates
Next, we further examined the antiviral activity of redoxal.
First, we tested its antiviral activity against the HIV-1 isolates
89BZ167 and 91US001, which demonstrated IC50s of 0.59 and
1.74 mM, respectively, and conﬁrmed the antiviral activity against
BaL (IC50 of 2.94 mM) shown in preceding experiments (Fig. 2B).
Therapeutic index values for redoxal ranged from 434 to 4168,
while AZT, included as a positive control, displayed a therapeutic
index ranging from 4225 to 4395 (Fig. 2B). To evaluate A3G-
dependent antiviral activity, redoxal was tested for its ability to
suppress HIV-1NL4-3 replication in spreading infections in non-
permissive CEM cells that express high levels of A3G and other
APOBEC3 proteins, and in permissive CEM-SS cells, a subclone of
CEM cells that expresses very low levels of A3G and other
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APOBEC3 proteins (Fig. 3A) (Refsland et al., 2010). Redoxal treat-
ment inhibited viral replication in a dose-dependent manner in
CEM cells but not CEM-SS cells, suggesting A3G-dependent anti-
viral activity. To further characterize dependence on A3G, we
examined A3G and Vif protein levels in redoxal-treated cells by
Western blotting of cell lysates at 3 and 6 days post infection
(Fig. 3B). Treatment with 1250 nM redoxal reduced Vif protein
levels in CEM cells, while A3G protein levels showed a modest
increase at 6 days post infection. High molecular weight (HMW)
forms of A3G were detected in redoxal-treated cells and virions
produced from these cells (Fig. 3C). These HMW forms might
represent Vif-induced polyubiquitinated A3G; in that case, the
decrease in cellular Vif protein levels detected at 6 days compared
to 3 days post-infection might explain the lack of HMW forms of
A3G detected at day 6. Redoxal treatment also increased A3G
incorporation into virions based on analysis of A3G in virions
produced from CEM cells and quantiﬁcation of virion-associated
A3G and p24Gag and the ratio of A3G:p24Gag proteins.
Redoxal attenuation of viral infectivity is augmented in cells
expressing A3G
To further characterize redoxal attenuation of HIV-1 replication
in T cells, we tested whether redoxal treatment enhances A3G
antiviral activity in a single-round infectivity assay. VSV-G pseu-
dotyped NL4-3GFPΔEnv viruses were produced in the presence of
A3G in redoxal-treated 293T producer cells. Similar to what we
observed in redoxal-treated CEM T cells, A3G protein levels were
elevated and Vif expression was suppressed in redoxal-treated
293T cells (Fig. 4A). Quantiﬁcation of HIV-1 particles produced
from these cells by RT assay demonstrated that redoxal treatment
also inhibited virus production (Fig. 4B). Equivalent amounts of
virus were used to infect TZM-bl reporter cells, which showed that
virions produced in redoxal-treated cells were less infectious than
virus particles produced in untreated cells (Fig. 4C). Redoxal
treatment reduced virus production and virion infectivity regard-
less of A3G expression (Fig. 4C). Redoxal inhibited HIV-1 infectivity
by approximately 20% in the absence of A3G and approximately
40% in the presence of A3G. These results, together with those of
Fig. 3A and other experiments suggest that about half of its
antiviral activity is achieved through A3G-dependent activity,
while the other half of its antiviral activity is A3G-independent.
Redoxal increases A3G protein stability in cells expressing HIV-1 Vif
Based on its identiﬁcation in a high-throughput screen
designed to identify inhibitors of Vif–A3G binding, we expected
that redoxal treatment would directly disrupt the Vif–A3G pro-
tein–protein interaction and hypothesized that this liberation of
A3G from Vif binding would directly lead to A3G stabilization. To
examine this possibility, 293Τ cells were co-transfected with Vif-
FLAG and A3G-HA plasmids and treated with 1250 nM redoxal for
40 h. As seen in the preceding experiments (Fig. 4A), redoxal
treatment abolished Vif-dependent A3G degradation (Fig. 5B,
upper panel). To test whether the increase in A3G protein could
be attributed to increased stability of the A3G protein, cyclohex-
imide (CHX) was used to arrest protein translation in cells and the
effects of redoxal treatment on A3G protein levels were monitored
over a 4-h time course. 293T cells were co-transfected with A3G-
3xHA and pNL4-3GFPΔEnv plasmids and treated with 1250 nM
redoxal for 36 h, followed by CHX treatment. Cells were harvested
at different time points and A3G and HIV-1 Vif protein levels were
examined in cell lysates by Western blotting followed by quanti-
tative analysis of protein levels using densitometry (Fig. 5A). The
CHX time course showed that steady-state levels of A3G protein
were stabilized by redoxal treatment, while in the absence of
Fig. 1. Identiﬁcation of redoxal and lomofungin as inhibitors of HIV-1 Vif–APOBEC3G interaction in a TR-FRET based assay: (A) TR-FRET based assay used to screen for
inhibitors of HIV-1 Vif–A3G interaction. The interaction between puriﬁed GST-Vif (amino acids 1–94) and biotinylated A3G peptide (amino acids 110–148, a surrogate for the
Vif binding site) was detected by Europium (Eu; donor ﬂuorophore)-labeled anti-GST antibody and streptavidin-UL (Ulight; acceptor ﬂuorophore). (B) Dose response TR-FRET
assay and counter screen testing of compounds redoxal and lomofungin for speciﬁcity and activity validation. The z-values calculated for the counter screens and cytotoxicity
assays ranged from 0.70 to 0.91. (C) Summary of redoxal and lomofungin including targets, known mechanisms of action, and structures.
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redoxal A3G levels were decreased by approximately 50%. In
contrast, redoxal had no signiﬁcant effect on Vif protein stability
(Fig. 5A).
Redoxal does not affect Vif interaction with A3G or Cullin 5 in cells
Contrary to expectations, co-immunoprecipitation of Vif and
A3G proteins from lysates of redoxal-treated versus untreated cells
did not reveal any signiﬁcant effect of redoxal treatment on Vif–
A3G interaction in cells (Fig. 5B, lower panel). However, the
experimental conditions of the co-immunoprecipitation assay are
markedly different from those of the TR-FRET assay, which could
affect the ability to detect Vif–A3G interaction. Because Vif–A3G
interaction did not appear to be affected by redoxal treatment yet
A3G was still liberated from Vif-mediated degradation, we next
determined whether redoxal was potentially affecting the ability
of Vif to interact with Cul5. Co-immunoprecipitation of HA-Cul5
from 293T cells expressing Vif-FLAG and HA-Cul5 indicated that
redoxal treatment has no effect on Vif–Cul5 interaction (Fig. 5C).
These results, together with the preceding experiments, suggest
that redoxal has no major effect on the interaction of Vif with A3G
or Cul5 proteins.
Redoxal exerts its effects on A3G antiviral activity through pyrimidine
depletion
Redoxal inhibits de novo pyrimidine synthesis by inhibiting
DHODH, the fourth enzyme of this pathway that converts dihy-
droorotate to orotate. Recent studies showed that other inhibitors of
pyrimidine biosynthesis are potent broad-spectrum antivirals
(Hoffmann et al., 2011; Lucas-Hourani et al., 2013). Therefore, we
explored the role of pyrimidine availability in regulation of A3G
protein levels in cells and virions by examining the effects of
supplementationwith uridine, which serves a central role in salvage
pathways for pyrimidine synthesis, and orotate, a pyrimidine
precursor. NL4-3GFPΔEnv viruses were produced in A3G-
expressing 293T cells treated with redoxal and supplemented with
uridine or orotate. A3G protein levels in cells and virions were
compared to those of untreated controls by Western blotting
followed by quantitative analysis of A3G protein levels using
densitometry. Consistent with preceding experiments (Fig. 5),
redoxal treatment increased A3G protein levels in virus producer
cells expressing HIV-1 Vif by approximately 50% (Fig. 6A and B). If
the effects of redoxal on A3G protein levels were related to its
ability to inhibit pyrimidine synthesis, we would expect to ﬁnd that
supplementation with uridine or orotate would reverse the effects
of redoxal treatment. Supporting this hypothesis, the effects of
Fig. 2. Redoxal and lomofungin inhibit HIV-1 replication in PBMCs: (A) Antiviral activity against HIV-1 replication in PBMCs. Redoxal and lomofungin were evaluated in
dose–response assays using a high-test concentration of 100 μM and half-log dilutions. AZT was included as a positive control antiviral compound. Treated PBMCs were
infected with HIV-1Ba-L isolate and 7 days post-infection virus replication and cell viability were measured by RT and MTS assays, respectively. Calculated values of the IC50,
TC50, and therapeutic index of the compounds are shown. (B) Redoxal exhibits broad antiviral activity against replication of diverse HIV-1 isolates in PBMCs. Antiviral activity
against replication of three HIV-1 isolates in PBMCs. Redoxal was evaluated in dose–response assays using a high-test concentration of 100 μM and half-log dilutions. Treated
PBMCs were infected with three HIV-1 isolates: Ba-L, 89BZ167, and 91US001. Seven days post-infection virus replication and cell viability were measured by RT and MTS
assays, respectively. AZT served as the positive control antiviral compound. Calculated values of tested compounds’ IC90, IC50, TC50 and therapeutic index are shown. Shown
in (A) and (B) are percentage of virus replication and cell viability in compound-treated cells relative to untreated controls. Results are representative of three independent
experiments each done in triplicate (upper panel; means of triplicate samples from independent wellsþSD).
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redoxal treatment on A3G protein levels were reversed by supple-
mentation with uridine (50 mM) or orotate (2 mM), while Vif and
p55Gag levels were not affected (Fig. 6A, upper panel, and Fig. 6B).
Furthermore, the increase in encapsidated A3G protein in virions
produced from redoxal-treated cells was reversed by treatment
with 50 mM uridine (Fig. 6A, lower panel). A3G has been detected in
exosomes, which have similar size and density as HIV-1 virions; the
results shown in Fig. 6A (lower panel) may therefore represent A3G
proteins in both HIV-1 virions and secreted exosomes (Coren et al.,
2008; Khatua et al., 2009). Consistent with these ﬁndings, an
approximately 50% decrease in the infectivity of NL4-3GFPΔEnv
viruses produced in redoxal-treated 293T producer cells was
reversed by treatment with 50 mM uridine or 2 mM orotate
(Fig. 6C and D). The moderate effect of 2 mM orotate compared to
50 uM uridine on diminishing redoxal antiviral activity is consistent
with another study (Lucas-Hourani et al., 2013). These results
suggest that redoxal augments A3G protein levels and antiviral
activity through its ability to inhibit pyrimidine synthesis.
To determine if redoxal treatment and uridine or orotate
supplementation have similar effects on A3G protein levels in
cells in the absence of Vif expression, we performed subsequent
experiments in 293T cells expressing A3G but not Vif or other viral
proteins. These experiments showed that A3G protein levels were
increased by redoxal treatment, while exposure to 50 μM uridine
or 2 mM orotate reversed this effect of redoxal (Fig. 7A and B). In
the absence of redoxal treatment, uridine or orotate treatment had
no signiﬁcant effect on A3G protein levels. Finally, we examined
whether pyrimidine depletion by redoxal treatment affected cell
viability. Treatment with redoxal (1250 nM) led to a 35% decrease
in cell viability, while orotate supplementation reversed this effect
in a dose-dependent manner, suggesting that pyrimidine deple-
tion by redoxal decreases cell viability (Fig. 7C).
Pyrimidine depletion by redoxal augments A3G protein stability
To assess whether pyrimidine depletion by redoxal increases
A3G protein stability in the presence or absence of Vif, 293T cells
were co-transfected with A3G-3xHA and pNL4-3GFPΔEnv (Fig. 8A)
or pCDNA3.1 (Fig. 8B) plasmids and treated for 36 h with or without
redoxal and uridine supplementation followed by CHX treatment.
At 0 or 4 h CHX treatment, cells were harvested to examine A3G
and HIV-1 Vif protein levels by Western blotting. In the presence
(Fig. 8A) or absence of HIV-1 Vif (Fig. 8B), CHX treatment had no
signiﬁcant effect on A3G protein levels in cells treated with redoxal
alone or supplemented with uridine, suggesting that pyrimidine
depletion induced by redoxal increases A3G protein stability
through a Vif-independent mechanism. In the absence of Vif
(Fig. 8B), redoxal appears to increase A3G more than in the presence
of Vif (Figs. 6A and 8A), which may be due to differences in the
experimental conditions, shorter exposure time of the blot in
Fig. 8B, and/or effects of redoxal on Vif-mediated A3G degradation.
Discussion
In this study, we report the initial characterization of two
compounds identiﬁed in a high-throughput screen for inhibitors of
Vif–A3G interaction (Fig. 1A). Both compounds potently sup-
pressed HIV-1 replication in PBMCs and human T cell lines.
Lomofungin is a natural product originally isolated from bacteria.
While the speciﬁc cellular targets of lomofungin have not been
identiﬁed, its inhibition of RNA synthesis is well characterized
(Cano et al., 1973; Johnson and Dietz, 1969; Klo et al., 1973) and it
has also been shown to inhibit the botulinum neurotoxin light
chain protease (Eubanks et al., 2010) and was identiﬁed as a
Fig. 3. Redoxal inhibits HIV-1 replication in an A3G-expressing T cells: (A) HIV-1 spreading infection in redoxal-treated T cells. CEM and CEM-SS T cells were infected with
HIV-1NL4-3 and 3 h post-infection cells were treated with 0, 312.5, 625, and 1250 nM redoxal. Virus production and cell viability of treated cells was tested at 3, 6, and 9 days
post-infection by RT and CellTiter-Glo assays, respectively. HIV-1 replication is shown in RT units. Percentage of cell viability in redoxal-treated cells is relative to untreated
controls (means of duplicate samples from independent wellsþSD). (B) Redoxal induces the appearance of high molecular weight forms of A3G protein in HIV-1 infected
CEM T cells. Infected cells treated with 0, 625, or 1250 nM redoxal were lysed 3 and 6 days post infection. Endogenous A3G, Vif, p55Gag, and β-tubulin protein levels in
infected cell lysates were analyzed by Western blotting. WCL: Whole Cell Lysates. (C) Redoxal induces the appearance of high molecular weight forms of A3G protein
incorporated into HIV-1 virions. Virions collected 3 and 6 days post infection were normalized for equivalent RT units and puriﬁed through 20% sucrose. A3G and p24Gag
protein levels in virion lysates were detected by Western blotting. *Values shown below A3G and p24Gag blots represent relative levels of virion-associated A3G protein in
virions produced in HIV-1 infected cells treated with redoxal were determined by densitometry of bands using ImageJ software and normalization to untreated cells (DMSO
control).
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Fig. 4. Redoxal attenuates virus production and infectivity: (A) Redoxal increases A3G protein levels in HIV-1 producer cells. 293T cells were co-transfected with 0.1 μg A3G-
3xHA and 1 μg pNL4-3GFPΔEnv HIV-1 plasmids using VSV-G envelope glycoprotein for pseudotyping. Five hours post-transfection, the media was replaced with fresh media
supplemented with DMSO or 1250 nM redoxal. At 40 h post transfection, supernatants containing virus were collected and producer cells were lysed. A3G, Vif, p24Gag, GFP
and β-tubulin protein levels in producer cell lysates were analyzed by Western blotting (B) Redoxal decreases viral particles produced independently of A3G expression.Virus
production from DMSO- and redoxal-treated cells was quantiﬁed by RT assay. Percentage of virus production is relative to virus production of untreated producer cells.
Results representative of two independent experiments each performed in duplicate. (C) Redoxal attenuates infectivity of viruses produced from cells expressing A3G
proteins. TZM-bl reporter cells were infected with viruses corresponding to 4000 RT units. Infectivity was measured 48 h post infection. Results are representative of two
independent experiments each done in triplicate. The percentage decrease in the infectivity of viruses produced from redoxal-treated cells compared to controls is shown
below the graph. Shown in (B) and (C) are meansþSD of duplicate samples from independent wells (P-values from Student’s t-test).
Fig. 5. Redoxal augments A3G protein stability without disrupting Vif interaction with A3G, or Cul5: (A) Redoxal augments A3G protein stability in cells expressing HIV-1 Vif.
293T cells were co-transfected with 100 ng A3G-3xHA and 1000 ng pNL4-3GFPΔEnv HIV-1 plasmids. At 5 h post transfection, the media was replaced with media
supplemented with 1250 nM redoxal. After 36 h of redoxal treatment, CHX was added. At the time intervals indicated after CHX treatment cells were lysed and A3G, Vif,
p55Gag, and β-tubulin protein levels were analyzed. Values shown below the blots represent relative A3G or Vif protein levels in treated cells determined by densitometry
using ImageJ software and normalization to A3G or Vif protein levels in untreated cells (DMSO control). (B) Redoxal does not disrupt Vif–A3G interaction in 293T cells. 293T
cells were co-transfected with 2000 ng pNLA1.Vif-FLAG and 300 ng A3G-3xHA or pCDNA3.1 (empty vector). The cells were then treated with 1250 nM redoxal for 40 h. At
48 h post transfection, cells were lysed and subjected to protein analysis. Western blot of cell lysates or anti-HA co-immunoprecipitated proteins were probed using anti-Vif
and anti-HA antibodies. (C) Redoxal does not affect Vif–Cul5 interaction in co-immunoprecipitation assays. 293T cells were co-transfected with 2000 ng pNLA1.Vif-FLAG and
either 4000 ng HA-Cullin 5 or pCDNA3.1 (empty vector) expression constructs. Transfected cells were treated with DMSO or 1250 nM redoxal for 40 h. Cells were lysed 48 h
after transfection. Cell lysates or anti-HA co-immunoprecipitated proteins were analyzed using anti-Vif and anti-HA antibodies.
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Fig. 6. Redoxal increases cellular A3G protein levels by inhibiting de novo pyrimidine biosynthesis: (A) Redoxal increases A3G protein levels in virus producer cells and newly
produced virions while uridine supplementation reverses these effects of redoxal. 293T cells were co-transfected with 100 ng A3G-3xHA and 1000 ng pNL4-3GFPΔEnv HIV-1
plasmids. At 5 h post transfection, the media was replaced with fresh media supplemented with DMSO or 1250 nM redoxal and supplemented with increasing doses of
uridine (0, 10, or 50 μM). At 40 h post transfection, supernatants containing virus were collected, producer cells were lysed, and A3G, Vif, p55 Gag, and β-tubulin protein
levels in producer cell lysates were detected by Western blotting (upper panels). Lower panels: A3G incorporation into virions produced from cells analyzed in the upper
panels. Virions normalized for equivalent RT units were puriﬁed through 20% sucrose and A3G and p24 Gag protein levels in virion lysates were detected byWestern blotting
(lower panels). Results are representative of two independent experiments. (B) Redoxal increases cellular A3G protein expression in virus producer cells while orotate
supplementation reverses this effect of redoxal. 293T cells were co-transfected with 100 ng A3G-3xHA and 1000 ng pCDNA3.1 (empty vector) plasmids. At 5 h post
transfection, the media was replaced with fresh media supplemented with DMSO or 1250 nM redoxal and supplemented with increasing doses of orotate (0, 0.5, or 2 mM).
At 40 h post transfection, cells were lysed. A3G and β-tubulin protein levels in cell lysates were analyzed by Western blotting. Results are representative of two independent
experiments. Values shown below blots in (A) and (B) represent relative A3G protein levels in treated cells determined by densitometry using ImageJ software and
normalization to A3G protein levels in untreated cells (DMSO control). (C) and (D) Redoxal attenuates infectivity of VSV-G pseudotyped NL4-3GFPΔEnv viruses produced in
A3G-expressing 293T cells, while uridine and orotate supplementation reverse this effect of redoxal. TZM-bl reporter cells were infected with viruses corresponding to 4000
RT units. Infectivity was measured 48 h post infection. Results are representative of two independent experiments each done in triplicate. Shown in (C) and (D) are
meansþSD of triplicate samples from independent wells (p-values from Student’s t-test).
Fig. 7. Uridine and orotate supplementation reverse the effects of redoxal on A3G protein levels in the absence of Vif: (A) Uridine supplementation diminishes redoxal-
induced augmentation of cellular A3G protein levels in the absence of HIV-1 Vif. 293T cells were co-transfected with 100 ng A3G-3xHA and 1000 ng pCDNA3.1 (empty
vector) plasmids. At 5 h post transfection, the media was replaced with fresh media supplemented with DMSO or 1250 nM redoxal and increasing doses of uridine (0, 10, or
50 μM). At 40 h post transfection, cells were lysed. A3G and β-tubulin protein levels in cell lysates were analyzed by Western blotting. Results are representative of two
independent experiments. (B) Orotate supplementation diminishes redoxal-induced augmentation of cellular A3G protein levels in the absence of HIV-1 Vif. 293T cells were
co-transfected with 100 ng A3G-3xHA and 1000 ng pCDNA3.1 (empty vector) plasmids. At 5 h post transfection, the media was replaced with fresh media supplemented
with DMSO or 1250 nM redoxal and supplemented with increasing doses of orotate (0, 0.5, or 2.0 mM). At 40 h post transfection, cells were lysed. A3G and β-tubulin protein
levels in cell lysates were analyzed by Western blotting. A3G blots are shown for two exposure times (20 and 60 s). Results are representative of two independent
experiments. Values shown below blots in (A) and (B) represent relative A3G protein levels in treated cells determined by densitometry using ImageJ software and
normalization to A3G protein levels in untreated cells (DMSO control). (C) Pyrimidine depletion by redoxal decreases cell viability. Viability of treated cells described in
Fig. 8B was measured using CellTiter-Glos Luminescent cell viability assay. Results are representative of two independent experiments. Shown are meansþSD of duplicate
samples from independent wells (p-values from Student’s t-test).
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potential therapeutic for myotonic dystrophy type 1 (Hoskins
et al., 2014b). However, its therapeutic potential is limited by
cytotoxicity, demonstrated in the present study as well as prior
studies. In an attempt to identify non-cytotoxic analogs, we
performed structure–activity relationship (SAR) studies (addi-
tional Files 2 and 3). We identiﬁed one lomofungin analog (analog
4) that exhibited antiviral activity against several HIV-1 isolates
and minimal cytotoxicity. However, this analog exerted only weak
antiviral activity. Therefore, further structural optimization is
needed to identify optimized compounds that may have stronger
antiviral activity and better therapeutic index.
Redoxal, the more potent compound identiﬁed in the present
study, demonstrated broad antiviral activity, inhibiting replication
of diverse HIV-1 isolates in PBMCs and T cell lines. Redoxal is a
known inhibitor of de novo pyrimidine synthesis (Cleaveland et al.,
1995; Zameitat et al., 2006) and redoxal treatment leads to
pyrimidine depletion in cells (Knecht and Lofﬂer, 2000). Pre-
viously, the antiviral effects of pyrimidine on nucleotide depletion
centered on decreased free nucleoside pools and potential
interference with viral synthesis of nucleic acids. However, in the
last several years, several groups have identiﬁed diverse molecules
that inhibit pyrimidine biosynthesis and suppress viral growth (A3
and DD264), with cellular proﬁles suggesting mechanisms of
antiviral resistance induction that extend beyond limitation of
free nucleosides (Hoffmann et al., 2011; Lucas-Hourani et al.,
2013). The antiviral activity of pyrimidine biosynthesis inhibitors
such as A3 and DD264 has been demonstrated mainly against RNA
viruses (e.g., inﬂuenza viruses A and B, Sendai virus, vesicular
stomatitis virus, hepatitis C virus, West Nile virus and Dengue I
virus), although some activity against DNA viruses (e.g., adeno-
virus 5, vaccinia, and a polyomavirus) has also been shown (DeVito
et al., 2014; Hoffmann et al., 2011; Lucas-Hourani et al., 2013).
Consistent with ﬁndings in the present study, earlier studies
showed that the pyrimidine synthesis inhibitors leﬂunomide (used
clinically as an immunosuppressive anti-rheumatic drug) and A3
have antiviral activity against HIV-1 (Hoffmann et al., 2011;
Schlapfer et al., 2003). Recent work has expanded our under-
standing of mechanisms through which these pyrimidine synth-
esis inhibitors lead to viral restriction. Based on recent studies, it
has become increasingly clear that intracellular skewing of nucleo-
side pools leads to a generalized antiviral state adopted by cells
(Lucas-Hourani et al., 2013). This antiviral state is mediated, at
least in part, through induction of well-characterized innate
immunity signaling networks that culminate in increased expres-
sion of intracellular defense genes mapping to the type I interferon
response pathway. Sensitization to apoptosis may occur in parallel
(Setzer et al., 2008), an effect that may contribute to the cytotoxic
effects we observed in redoxal-treated cells.
Redoxal exhibited stronger antiviral activity in the presence of
A3G expression, suggesting involvement of an A3G-dependent
mechanism and consistent with identiﬁcation of redoxal in a high
throughput screen targeting Vif–A3G interaction. However, we
also found that about half of its antiviral activity was A3G-
independent, suggesting that protective effects of redoxal are
likely to be pleiotropic. Redoxal's A3G-independent activity may
target the virus at a post-integration step(s) prior to virion
maturation, such as the step of transcription, similar to the
pyrimidine synthesis inhibitor A3 (Hoffmann et al., 2011). Explor-
ing its molecular mechanism of action revealed an unexpected
stabilization of A3G protein in redoxal-treated cells. Contrary to
expectations, speciﬁc disruption of the Vif–A3G interaction was
not detected, although Vif protein levels appeared to be moder-
ately suppressed while A3G protein levels were increased. Impor-
tantly, pyrimidine depletion induced by redoxal not only increased
cellular A3G protein levels; its anti-HIV-1 activity was also
enhanced. To our knowledge, this is the ﬁrst report to identify a
direct link between induction of a generalized antiviral state via
inhibition of pyrimidine biosynthesis and a speciﬁc cellular
restriction factor.
The antiviral mechanisms induced by redoxal have not been
characterized in detail, nor have the direct intracellular targets been
identiﬁed. Redoxal-mediated restriction of HIV-1 appears to affect
late steps in the viral replication cycle, consistent with previous
studies of the pyrimidine synthesis inhibitor A3 (Hoffmann et al.,
2011). In unpublished preliminary experiments, redoxal did not
disrupt Vif–CBFβ interaction in co-immunoprecipitation experi-
ments similar to those shown in Fig. 5. However, further studies
are needed to determine if CBFβ has any role in redoxal's antiviral
activity. Redoxal treatment may also impair protein degradation
(Tolstonog and Deppert, 2010). In the presence of redoxal, we
detected high molecular weight forms of A3G that might represent
mono- and polyubiquitinated A3G proteins, potentially rescued
from proteasomal degradation and accumulating in infected cells
and newly produced viruses. The possibility that these alternate
forms of A3G represent ubiquitinated proteins and their functional
Fig. 8. Pyrimidine depletion induced by redoxal increases A3G protein stability:
(A) Pyrimidine depletion by redoxal augments A3G protein stability in virus
producer cells. 293T cells were co-transfected with 100 ng A3G-3xHA and
1000 ng pNL4-3GFPΔEnv HIV-1 plasmids. At 5 h post transfection, the media was
replaced with fresh media supplemented with DMSO or 1250 nM redoxal and
supplemented with uridine (0, 10 or 50 μM) for 36 h followed by CHX treatment. At
0 and 4 h post CHX treatment, cells were lysed. A3G, Vif, p55 Gag, and β-tubulin
protein levels in producer cell lysates were detected by Western blotting.
(B) Pyrimidine depletion by redoxal augments A3G protein stability in the absence
of Vif. 293T cells were co-transfected with 100 ng A3G-3xHA and 1000 ng
pCDNA3.1 (empty vector) plasmids. At 5 h post transfection, the media was
replaced with fresh media supplemented with DMSO or 1250 nM redoxal and
supplemented with uridine (0, 10 or 50 μM) for 36 h followed by CHX treatment. At
0 and 4 h post CHX treatment, cells were lysed. A3G and β-tubulin protein levels in
cell lysates were analyzed by Western blotting. Results are representative of two
independent experiments. Values shown below blots in (A) and (B) represent
relative A3G or Vif protein levels in treated cells determined by densitometry using
ImageJ software and normalization to A3G or Vif protein levels in untreated cells
(DMSO control). Results shown in (A) and (B) are representative of two indepen-
dent experiments.
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signiﬁcance will be addressed in future studies. Most intriguing is
the newly identiﬁed link between disruption of the intracellular
nucleoside availability and initiation of a potent innate antiviral
response through A3G-dependent as well as A3G-independent
mechanisms. It is interesting to consider whether cellular pyrimi-
dine depletion by redoxal treatment of A3G-expressing T cells
initiates an antiviral program through induction of an as yet
unidentiﬁed pathway that culminates in augmentation of A3G, a
potent restriction factor mediating innate immunity, leading to
enhanced restriction against an invading retrovirus. For example,
pyrimidine depletion may induce mismatch repair, leading to a DNA
damage response and activation of DNA-damage-induced signaling
pathways that could be involved in regulating A3G stability
(Franchini and Petersen-Mahrt, 2014).
In summary, we identiﬁed lomofungin and redoxal as novel
inhibitors of HIV-1 replication. Studies exploring the mechanisms
mediating redoxal antiviral activity suggest that inhibition of
pyrimidine biosynthesis and limited pyrimidine availability
increase cellular A3G protein stability and antiviral activity,
thereby restricting HIV-1 infection. A better understanding of the
connections between dysregulation of cellular nucleoside pools
and induction of the innate restriction factor A3G may provide




HEK293T cells (ATCC) were grown in DMEM supplemented
with 10% fetal bovine serum and 1% penicillin/streptomycin. TZM-
bl cells (obtained through the NIH AIDS Reagent Program, Division
of AIDS, NIAID, NIH: TZM-bl from Dr. John C. Kappes, Dr. Xiaoyun
Wu and Tranzyme Inc.(Wei et al., 2002)) were grown in DMEM
supplemented with 10% FBS and 1% penicillin/streptomycin. The T
cell lines H9, CEM, CEM-SS, and SupT1 (obtained through the NIH
AIDS Reagent Program) were grown in RPMI 1640 supplemented
with 10% FBS and 1% penicillin/streptomycin. Fresh human PBMCs
were isolated as previously described (Ptak et al., 2008) from
screened donors, seronegative for HIV and HBV (Biological Speci-
alty Corporation, Colmar, PA) and grown in RPMI 1640 supple-
mented with 15% FBS, 2 mM L-glutamine, 100 U/mL penicillin, and
100 μg/mL streptomycin; cells were stimulated with 4 μg/mL
phytohemagglutinin (PHA; Sigma-Aldrich) for 48–72 h and cul-
tured in RPMI 1640 supplemented with 15% FBS, L-glutamine,
penicillin, streptomycin, non-essential amino acids (MEM/NEAA;
Hyclone) and 20 U/mL recombinant human IL-2 (R&D Systems
Inc.) for 48 h before infection.
Antibodies and plasmids
The following antibodies were used: rabbit anti-Vif (Goncalves
et al., 1994), rat 3F10 anti-HA (Roche Applied Science), mouse anti-
tubulin (Sigma-Aldrich), mouse anti-GFP (Zymed), and rabbit anti-
APOBEC3G (obtained through the NIH AIDS Reagent Program,
Division of AIDS, NIAID, NIH: anti-APOBEC3G-C terminal from Dr.
Jaisri Lingappa). pNL4-3-GFP is pNL4-3, an HIV-1 proviral DNA
containing plasmid, with an env-inactivating mutation and
enhanced green ﬂuorescent protein (eGFP) replacing nef (He
et al., 1997). pNLA1.Vif-FLAG was a gift from Strebel (Strebel,
2013). pCMV4.APOBEC3G-HA was a gift from M. Malim (Sheehy
et al., 2002). pCDNA3-HA-Cul5 was a gift from J. Conaway. The
pGEX.6P.1 expression vector (Novagen) expresses Vif residues 1–
94.
Cell transfection, Western Blot analysis, and co-immunoprecipitation
HEK293T cells were cultured in DMEM with 10% FBS and
transfected by lipofectamine 2000 (Life Technologies) according to
the manufacturer's instructions. 40–48 h post transfection, cells
were lysed in lysis buffer (50 mM Tris–HCl, pH 7.0, 150 mM NaCl,
0.5% Nonidet P-40, and 1% protease inhibitor mixture). Twenty-ﬁve
micrograms of protein normalized by Bradford protein assay (Bio-
Rad) was separated by SDS-PAGE, transferred onto polyvinylidene
diﬂuoride (PVDF) membranes (Millipore), and detected by standard
Western blotting. For co-immunoprecipitation experiments, iden-
tical amounts of lysate were subjected to immunoprecipitation
followed by Western blotting. HA- and FLAG-tagged proteins were
immunoprecipitated by EZview Red Anti-HA Afﬁnity Gel (Sigma-
Aldrich) and FLAG-Immunopecipitation Kit (Sigma-Aldrich).
High-throughput screen for inhibitors of Vif–APOBEC3G interaction
The homogeneous time-resolved ﬂuorescence energy transfer
(TR-FRET) assay for inhibitors of Vif–A3G interaction was pre-
viously described (Pery et al., 2015). Brieﬂy, the interaction
between GST-Vif residues 1–94, which contains the A3G binding
site, and a biotinylated peptide consisting of A3G residues 110–148
was detected using TR-FRET (Mehle et al., 2007; Pery et al., 2009).
The 1–94 GST-Vif was expressed and puriﬁed from E. coli as
described (Pery et al., 2009). A 307,520 compound library (NIH
Molecular Libraries Small Molecule Repository (MLSMR)) was
screened at 6.25 mM and hits were selected based on percent
inhibition of 1–94 GST-Vif and A3G peptide interaction as
described (Pery et al., 2015). Candidates were further evaluated
for dose–response (ranging between 0.195 and 100 μM) in a
counter screen to exclude compounds attenuating the TR-FRET
signal independently of Vif–A3G interaction, and in an HIV-1 Tat-
TAR Fluorescence Polarization (FP) assay to aid in selecting
compounds with speciﬁcity for the Vif–A3G interaction. Candi-
dates were also evaluated in a cell toxicity assay. Detailed methods
of the counter screens and cytotoxicity screens have been
described (Pery et al., 2015).
HIV-1 replication in peripheral blood mononuclear cells
Compounds were evaluated in dose–response assays using a
100 μM high-test concentration as described (Ptak et al., 2008).
AZT was included as a positive control. Activated PBMCs were
plated at 5104 cells/well in 96-well plates. An MOI of 0.1 of
HIV-1Ba-L (lab-adapted, Group M, Subtype B, CCR5-tropic; from the
NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH, courtesy
of Drs. Suzanne Gartner, Mikulas Popovic, and Robert Gallo
(Gartner et al., 1986)), or one of the following HIV-1 isolates from
the NIH AIDS Reagent Program: HIV-1NL4-3 (lab-adapted, Group M,
Subtype B, CXCR4-tropic; from Dr. Malcolm Martin), HIV-1
89BZ167 (clinical isolate, Group M, Subtype B, CXCR4-tropic; from
the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH,
courtesy of Dr. John Mascola (Louwagie et al., 1994)), or HIV-1
91US001 (alternative designations US1 (GS 004) or 91US_1;
clinical isolate, Group M, Subtype B, CCR5-tropic from the NIH
AIDS Reagent Program, Division of AIDS, NIAID, NIH, courtesy of
Dr. Nelson Michael (Jagodzinski et al., 2000; Michael et al., 1999;
Vahey et al., 1999)) was then added to each test well. Primary virus
stocks were prepared by low-passage replication in fresh PBMCs.
Parallel plates without virus were prepared and monitored for cell
viability using MTS (CellTiter 96 Reagent, Promega). PBMC cultures
were maintained for 7 days at 37 1C, 5% CO2. Cell-free supernatants
were then collected and analyzed for reverse transcriptase (RT)
activity (Buckheit and Swanstrom, 1991), while cytotoxicity was
measured by MTS assay.
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HIV-1 replication in T cells
NL4-3 (X4-tropic) viruses were produced in HEK293T cells and
viral titers were measured by RT assay as described (Goncalves
et al., 1996). Virus stocks of 1105 3H cpm and 2104 3H cpm
were used to infect 106H9 or SupT1 T cells, respectively. 3 h post
incubation at 37 1C, 5% CO2, infected cells were washed 3 to
remove cell-free virus and 100 μL of infected cells were added to
wells in 96-well plates. Lomofungin (Enzo Life Sciences) was
evaluated in dose–response assays using a 250 nM high-test
concentration. The protease inhibitor Ritonavir was included as a
positive control (obtained through the NIH AIDS Reagent Pro-
gram). Plates without virus were prepared in parallel for cytotoxi-
city assays. Cells were incubated for 6 days, and virus production
was measured using p24 ELISA (PerkinElmer) according to the
manufacturer's instructions; cytotoxicity was measured by CellTi-
ter-Glos assay. Redoxal (Sigma Aldrich) was evaluated for anti-
viral activity during spreading infections in CEM and CEM-SS T
cells infected with HIV-1NL4-3. At 3 h post-infection, cells were
treated with increasing concentrations of redoxal and virus pro-
duction and viability of treated cells was tested at 3, 6, and 9 days
post-infection by RT and CellTiter-Glos assays.
Viral infectivity assay and virus puriﬁcation
Viruses were produced by co-transfecting HEK293T cells with
VSV-G envelope glycorprotein, pCMV4.APOBEC3G-HA, and pNL4-
3GFPΔEnv HIV-1 plasmids (He et al., 1997). Viruses were quanti-
ﬁed by RT assays, and normalized amounts were used to infect the
reporter cell line TZM-bl. Infectivity was measured 48 h after
infection by performing luciferase (Promega) or β-galactosidase
assays (Applied Biosystems). To purify viruses, 1.5105 cpm virus-
containing supernatants were concentrated by ultracentrifugation
through 20% sucrose in phosphate-buffered saline (PBS). Puriﬁed
viruses were resuspended in Laemmli sample buffer supplemen-
ted with 5% β-mercaptoethanol. p24Gag and A3G protein levels in
puriﬁed virus particles were detected by Western blot.
Statistical analysis
Statistical signiﬁcance was determined using Student’s unpaired
2-tailed t-test, with results presented as means of duplicate or
triplicate independent wells or samples. Error bars represent
standard deviations. P-values o0.05 were considered signiﬁcant.
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